Abstract-Cytochrome P 450 epoxygenases convert arachidonic acid into 4 epoxyeicosatrienoic acid (EET) regioisomers, which were recently identified as endothelium-derived hyperpolarizing factors in coronary blood vessels. Both EETs and their dihydroxyeicosatrienoic acid (DHET) metabolites have been shown to relax conduit coronary arteries at micromolar concentrations, whereas the plasma concentrations of EETs are in the nanomolar range. However, the effects of EETs and DHETs on coronary resistance arterioles have not been examined. Key Words: epoxyeicosatrienoic acids Ⅲ dihydroxyeicosatrienoic acids Ⅲ arachidonic acid Ⅲ endothelium-derived hyperpolarizing factor Ⅲ coronary microcirculation A rachidonic acid (AA) can be converted to vasoactive metabolites through several enzymatic pathways, including the cyclooxygenase, lipoxygenase, and cytochrome P 450 pathways. Cytochrome P 450 epoxygenases convert AA to 4 epoxyeicosatrienoic acid (EET) regioisomers, 5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET, corresponding to the carbons where the epoxide group is formed. 1,2 EETs have been shown to relax coronary, cerebral, renal, and pial arteries, and they also hyperpolarize vascular smooth muscle cells. 38 In conduit coronary blood vessels, both vasorelaxation and hyperpolarization may be mediated by activation of calcium activated K ϩ (K ca ) channels. 5 By virtue of these properties, EETs are considered to be candidates for endothelium-derived hyperpolarizing factors (EDHF). 9 -11 EETs are converted rapidly by vascular endothelial and smooth muscle cell epoxide hydrolases to dihydroxyeicosatrienoic acids (DHETs), 12, 13 which are devoid of vasoactive properties in noncoronary blood vessels. 14 -16 However, in porcine conduit coronary arteries contracted with U46619, DHETs produce comparable amounts of relaxation as their parent EETs. 17, 18 The relaxation responses were observed predominately at micromolar concentrations of DHETs, as reported previously for the 4 EET regioisomers in canine conduit coronary arteries.
Other investigators have demonstrated that the contribution of EDHF to endothelium-dependent responses is greater in small arteries than in large arteries. 5, 21, 22 Thus, taken together, these studies suggest that the vasodilatory role of EETs and DHETs may be more important in coronary microcirculation than in conduit coronary blood vessels.
In the present study, we examined responses to EETs and DHETs in isolated canine coronary arterioles (diameter, Ͻ125 m) preconstricted with endothelin. In contradistinction to coronary conduit arteries, resistance coronary arterioles were found to dilate to extremely low (picomolar) concentrations of EETs and DHETs, suggesting that these cytochrome P 450 metabolites may contribute importantly to vasoregulation of the coronary circulation. We also examined potential mechanisms involved in the potent EET-induced coronary microvascular dilation.
Materials and Methods
All animal protocols were approved by the University of Iowa Animal Care and Use Committee and conform with the Guide for the Care and Use of Laboratory Animals published by the NIH (NIH publication No. 85-23, revised 1985) .
Synthesis of EETs and DHETs
Vasoactivity was tested using radiolabeled EETs and DHETs to permit confirmation of the final concentrations by liquid scintillation techniques. The radiolabeled eicosanoids were synthesized, using methods originally developed for unlabeled compounds. 23, 24 The radiolabeled EET regioisomers were synthesized from methylated arachidonate (American Radiolabeled Chemicals, St Louis, Mo). In brief, [1- 14 C]AA was mixed with AA to a specific activity of 12.3 Ci/mol and methylated using ethereal diazomethane. The methylated arachidonate was mixed with 0.2 equivalents of m-chloroperoxybenzoic acid, and the resulting EET methyl esters were extracted, resolved by silicic acid high-performance liquid chromatography (HPLC), and collected. The isolates were saponified, again resolved by silicic acid HPLC, collected, and stored in methanol at Ϫ80°C until use.
The radiolabeled DHET regioisomers were synthesized from the corresponding [1- 14 C]EET methyl esters. The epoxide ring first was hydrolyzed at 40°C for 16 hours in the presence of acetic acid, and the remaining methyl ester was removed by saponification. Each DHET regioisomer was subjected to silicic acid HPLC, collected, and stored in methanol at Ϫ80°C until use.
Based on absorption at 192 nm during reversed-phase HPLC and radioassays of collected fractions, 24 the combined normal-phase HPLC procedures produced regioisomers with Ͼ98% chemical and radiopurity. The identity of each regioisomer was established by coelution with unlabeled standards during HPLC and gas chromatography and by mass spectrometry.
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Procurement of Tissue
Seventy-two adult mongrel dogs of either sex (8 to 25 kg) were euthanized with sodium pentathol (50 mg/kg). The hearts were harvested quickly and placed immediately in cold (4°C), oxygenated (20% O 2 ; 5% CO 2 ; 75% N 2 ) Krebs bicarbonate buffer solution (see details below). Ventricular arterioles (60 to 150 m; mean diameter, 90Ϯ3.4 m) were dissected, trimmed of fat and connective tissue, and transferred to organ chambers.
Isolated Microvessel Preparation
A pressurized arteriole preparation was used to study the isolated coronary microvessels. 26 Each end of the arteriole was cannulated with a glass micropipette. The cannulated pipettes were attached to a hydrostatic pressure reservoir under conditions of no flow. The organ chamber was placed on the stage of an inverted microscope, to which a video camera, monitor, and calibrated caliper were attached.
The organ chamber was connected to a rotary pump, which continuously circulated oxygenated Krebs buffer warmed to 37°C. Internal diameters were measured by manually adjusting the video micrometer.
Each arteriole was allowed to equilibrate for 30 minutes at a distending pressure of 20 mm Hg. KCl (50 mmol/L) was added to the bath to test constrictor capacity. When stable levels of constriction were reached, the chambers were rinsed and the arterioles allowed to return to baseline diameter. Endothelin-1 (0.40 to 8.0 nmol/L) was used to constrict the arterioles to 30% to 60% of their resting diameters. Cumulative concentration-response relationships were evaluated for AA ( Ϫ10 Ϫ10 Ϫ4 mol/L) by adding the drugs directly to the organ chambers. In separate experiments, concentration-response curves were performed using the 4 EET regioisomers and 8,9-DHET, 11,12-DHET, and 14,15-DHET regioisomers, as well as the 5,6-EET-methyl ester, and the ␦-lactone of 5,6-EET (10 Ϫ18 to 10 Ϫ6 mol/L). After completing the concentrationresponse studies, a single dose of SNP (100 mol/L) was applied; in the KCl depolarization and charybdotoxin experiments, papaverine (100 mol/L) was also administered. Arterioles were considered to be unacceptable for experimentation if they (1) demonstrated obvious leaks, (2) failed to constrict Ͼ50% to 50 mmol/L KCl and Ͼ30% to endothelin, or (3) failed to dilate Ͼ80% to 100 mol/L SNP or papaverine.
In some studies, we examined whether the vasodilatory responses produced by 14,15-EET required an intact endothelium. Before microvessel cannulation, the endothelium was denuded by passing a thin wire several times through the vascular lumen. The endothelium was considered to be functionally denuded when bradykinin (1 mol/L) produced Ͻ10% dilation. Damage to underlying smooth muscle was considered minimal if SNP (100 mol/L) produced Ͼ80% dilation.
In other experiments, we examined whether epoxide hydrolase inhibitors altered the dilation response induced by EET. Responses to 11,12-EET were determined in the presence of vehicle (dimethyl sulfoxide [DMSO]) or 20 mol/L 4-phenylchalone oxide (4-PCO), an inhibitor of epoxide hydrolases. 27 To examine the role of K ϩ channels in EET-and DHET-induced vasodilation, arteriolar responses to 11,12-EET and 11,12-DHET were performed in vessels depolarized with isotonic KCl solutions (prepared by substituting equimolar amounts of KCl for NaCl) or in endothelin-preconstricted vessels treated with 50 nmol/L charybdotoxin.
Isolated Vascular Rings
Coronary arteries were studied using a common isometric ring technique. 5, 18, 26 Vascular rings (OD, 1.0 to 1.5 mm) were mounted on 2 stirrups made by passing stainless steel wires through the vessel lumen. One stirrup was attached to a force transducer and the other to a micrometer microdrive for stretching the vessel by known increments. Each vessel apparatus was placed in a 10-mL waterjacketed organ bath containing Krebs buffer equilibrated at 37°C and aerated with 20% O 2 , 5% CO 2 , and 75% N 2 . Isometric contractions and relaxations were measured using a computer. Rings were individually stretched to the maximum of the length-developed tension relationship by repeated test exposures to 75 mmol/L KCl at increasing vessel diameters.
The vessels were allowed to stabilize for 30 minutes before performing concentration response curves. PGF 2␣ was used to constrict the vessels to 30% to 50% of their resting tension. After steady-state tension was achieved, concentration-response relationships were evaluated for several of the vasodilators used in the microvessel studies, including AA ( 3 H is present at carbons 5, 6, 8, 9, 11, 12, 14, and 15. The "14,15-" refers to the location of the epoxide group.) After 1 hour, 50-L aliquots of the incubated solution were collected to determine total radioactivity by scintillation counting. Lipids were extracted from the incubation solution using 4-vol water-saturated ethyl acetate. Phases were separated by centrifugation at 600g for 10 minutes, and the ethyl acetate phase was collected and evaporated under N 2 . The lipid extracts were resuspended in acetonitrile and stored at Ϫ20°C until analysis by HPLC.
Lipids were separated by reverse-phase HPLC using a Gilson 302 pump plus 2050 UV detector, and a 2.1ϫ150-mm C 18 column containing 3-m spherical particles of EQC (Alltech). The elution profile, developed with a Gilson 715 gradient controller, consisted of water adjusted to pH 3.4 with phosphoric acid and an acetonitrile gradient increasing from 25% to 100% over 60 minutes at a flow rate of 0.4 mL/min. Radioactivity was measured by combining the column effluent with Budget-Solve TM solution and passing the mixture through a Radiomatic Flo-One Beta isotope detector, as described previously. 17, 18 The amount of 14,15-DHET formed (normalized to ring wet weight) was calculated from the specific activity of the radiolabeled 14,15-EET used in the incubation. In some experiments, the radiolabeled 14,15-EET was incubated under the same conditions but in the absence of coronary artery rings. No 
Solutions and Test Compounds
All solutions were prepared on the day of the experiment. Krebs solution contained (in mmol/L): NaCl 131.5; KCl 5; CaCl 2 2.5; MgCl 2 1.2; NaHCO 3 23.5; KH 2 PO 4 1.2; and glucose 11, pH 7.4. Aerated with 20% O 2 , 5% CO 2 , and 75% N 2 , Krebs solution was maintained at 37°C. Endothelin-1 was purchased from Calbiochem. Ach, A23187, AA (sodium salt), bradykinin, SNP, and charybdotoxin were purchased from Sigma Chemical Co. 4-PCO was purchased from Biomol. Reference unlabeled EETs, DHETs, and the ␦-lactone of 5,6-DHET were purchased from Cayman Chemicals.
[ 3 H]14,15-EET was purchased from Dupont-New England Nuclear Corp. For all organ chamber studies in which EETs or their metabolites were used, with the exception of those studies with 5,6-EET, the solvents were evaporated under nitrogen to yield 5-mol/L stock solutions, which were suspended in the Krebs buffered solution immediately before being subjected to serial dilutions. In contrast, the chemically labile 5,6-EET was applied directly in ethanol (Ͻ0.01% final concentration), using a Hamilton syringe.
Statistical Analysis
All concentration response curves were evaluated for changes in maximal responses and differences at each dose using ANOVA with repeated measures plus a Bonferroni correction for multiple comparisons. EC 10 and EC 50 values (defined as the concentration that produced 10% and 50% of maximal vasodilation of the endothelin preconstriction, respectively) were calculated and expressed as Ϫlog [M] . Differences between mean EC 10 and EC 50 values were assessed using the Student t test or 1-way ANOVA where appropriate. All data are expressed as meanϮSEM. A P value of Ͻ0.05 was considered significant.
Results
All EETs and DHETs produced concentration-dependent dilation of pressurized, endothelin-preconstricted canine coronary arterioles. Significant vasodilation to 11,12-EET was observed after administration of subpicomolar concentrations, and the calculated EC 10 and EC 50 values were 
Endothelium-intact canine coronary arterioles preconstricted with endothelin were exposed to increasing concentrations of one of the EET or DHET regioisomers, and changes in diameter were measured. The ␦-lactone of 5,6-DHET was tested (rather than 5,6-DHET) because it is the major 5,6-EET product due to an enhanced chemical stability of the lactone arising from formation of a 6-membered ring. EC 10 Table 1 ). The maximum amount of vasodilation with 1 mol/L 11,12-EET was 73Ϯ6%. In contrast to these findings, the EET vehicle (ethanol) at the highest concentration of vehicle administered produced only a modest amount of vasodilation (25Ϯ2%).
Responses to 11,12-DHET, the diol metabolite of 11,12-EET, were determined and compared with those produced by the parent EET. Surprisingly, 11,12-DHET was more potent than its parent compound at every concentration tested (Figure 1 ). Moreover, with substantial vasodilation occurring at a concentration of Ϸ10 Ϫ18 mol/L, 11,12-DHET was the most potent agent tested in this study. The calculated EC 10 and EC 50 values were Ϫ17.8Ϯ0.6 and Ϫ15.8Ϯ0.7 (log [M]), respectively (Table 1) . Thus, comparisons of the EC 10 and EC 50 values indicated that the 11,12-diol was 13 000-to 1 000 000-fold more potent than the parent 11,12-epoxide (Table 1) . Maximal vasodilation was observed at 100 pmol/L 11,12-DHET; at this concentration, the diameter of the arteriole was essentially that of the preconstricted state.
Next, we examined responses to 5,6-EET and the ␦-lactone of 5,6-EET. Similar to the results obtained with 11,12-EET, significant vasodilation occurred at subpicomolar concentrations of 5,6-EET, and the calculated EC 10 Table 1 ). Maximal vasodilation was 91Ϯ9% and occurred with a concentration of 1 mol/L. Surprisingly, the ␦-lactone was found to be at least as potent as the parent 5,6-EET (41Ϯ12% vasodilation at 0.01 pmol/L; EC 50 (log [M])ϭϪ13.3Ϯ0.8). Vasodilation (100%) to the ␦-lactone occurred at 100 pmol/L. We did not investigate responses to 5,6-DHET, because this compound is known to rapidly rearrange to the ␦-lactone in aqueous solutions. 28 However, to assess whether the neutral lactone's sustained potency was largely due to an enhanced lipophilicity at pH 7.4, we examined the potency of the neutral 5,6-EET methyl ester (5,6-EET-ME). The latter compound produced vasodilation that is somewhat less potent than that produced by the ␦-lactone; PϽ0.05 ( Figure 2 , Table 1 ). Thus, the high potency of the 5,6-DHET lactone was not simply due to removal of the anionic charge, and the DHET product remained as potent as the parent EET.
Responses to the remaining 2 EET regioisomers, 8,9-EET and 14,15-EET, and their diol metabolites, were also determined. All 4 compounds were found to be potent vasodilators of canine coronary arterioles ( Figure 3 , Table 1 ). Similar to 11,12-DHET, 8,9-DHET possessed an EC 10 that was lower than its EET precursor (Table 1) ; that is, the 8,9-diol was slightly more potent than its 8,9-epoxide precursor in initiating vasodilation. However, at the higher concentrations the DHET and EET curves tended to overlap ( Figure 3A) , and the 8,9-DHET EC 50 {Ϫ13.1Ϯ0.7 (log [M])} was essentially the same as that of 8,9-EET (Ϫ11.0Ϯ0.4 {log [M])}. Although the concentration-response curve of 14,15-DHET tended to be to the left of the parent 14,15-EET (Figure 3B ), the 2 compounds were equipotent (Pϭ0.09).
To address whether EET-induced vasorelaxation is dependent on the presence of endothelium, we examined responses to 14,15-EET in endothelium-denuded coronary arterioles. Denuded microvessels did not respond to bradykinin (1 mol/L); however, SNP (100 mol/L) produced 94Ϯ3% relaxation. Despite the absence of functional endothelium, 14,15-EET produced potent vasodilation that did not differ significantly from the responses observed in endothelium- ; maximal vasodilationϭ77Ϯ3% at 1 mol/L, respectively (nϭ5 for both groups). These data suggest that the 11,12-EET-induced vasodilation is not dependent on conversion of the regioisomer to 11,12-DHET.
Further studies were performed to investigate the role of K ϩ channels in EET-and DHET-induced coronary microvascular dilation. Canine coronary arterioles were constricted with endothelin or isotonic KCl solution (35Ϯ2 mmol/L) to 30% to 60% of their resting diameter. 11,12-EET or 11,12-DHET was administered in a concentration-dependent manner. KCl depolarization abolished the dilation to 11,12-EET ( Figure 5A ) and 11,12-DHET ( Figure 5B) .
We also examined the effects of charybdotoxin, an inhibitor of K Ca channels, on EET-and DHET-induced vasodilation. Responses to 11,12-EET ( Figure 5C ) and 11,12-DHET ( Figure 5D ) were attenuated in the presence of 50 nmol/L charybdotoxin by 59% and 56%, respectively. Together, these data suggest that EET-and DHET-induced microvascular relaxation involves activation of vascular smooth muscle K Ca channels.
Responses to AA (the precursor of EETs and DHETs), calcium ionophore (A23187), Ach, and SNP were also determined. AA produced concentration-dependent vasodilation, with Ϸ20% and 90% dilation at concentrations of 1 nmol/L and 10 mol/L, respectively. The calculated EC 50 value for AA was Ϫ7.5Ϯ0.4 (log [M]) (Table 2) , which was 1000-to 10 000-fold less than found for the EETs and their DHET products. All of the other vasodilators also produced concentration-dependent vasodilation of endothelinpreconstricted microvessels. However, 11,12-DHET was far more potent than all of these compounds tested. It is interesting that the potency of A23187 approached those of other EETs and their metabolites ( Table 2) . A23187 was more potent than Ach, AA, and SNP.
Responses to AA, A23187, Ach, SNP, and 11,12-DHET also were determined in PGF 2␣ -constricted conduit coronary arterial rings. AA and SNP produced complete relaxation of the conduit arterial rings, whereas Ach and A23187 produced 89Ϯ4% and 78Ϯ7% relaxation, respectively, at the highest concentrations studied (100 and 1 mol/L respectively). EC 50 values of these agents are shown in Table 2 . Up to 0.1 mol/L 11,12-DHET produced minimal relaxation (24Ϯ13%) of PGF 2␣ -constricted conduit arterial rings; at higher concentrations, 11,12-DHET actually constricted the vessels. As was observed in microvessels, A23187 was more potent than SNP, Ach, and AA in conduit vessels.
Discussion
There are several major findings in the present study. First, all 4 EET regioisomers produced extremely potent, concentration-dependent dilation of isolated canine coronary arterioles. The vasodilation produced by 14,15-EET was not attenuated by removal of the endothelium, suggesting a direct action of the compound on microvascular smooth muscle cells. Second, the major EET metabolites, DHETs, each produced vasodilation that was at least as potent as that produced by the parent EETs. However, suppression of DHET formation by inhibition of epoxide hydrolases did not attenuate 11,12-EET-induced vasodilation, suggesting that the potent 11,12-EET-induced vasodilation is not dependent on conversion to 11,12-DHET. Third, vasodilation produced by 11,12-EET and 11,12-DHET was blocked by depolarization with KCl or charybdotoxin, suggesting that the responses were mediated by activation of K Ca channels. Finally, the potency of EETs and DHETs to dilate coronary arterioles was found to be far greater than the potency reported for conduit coronary arteries. Together, these findings suggest that EETs and their diol metabolites may importantly regulate the coronary microcirculation.
Rosolowsky et al 3 reported that in canine conduit coronary arteries contracted with U46619, the 4 EETs produced endothelium-independent relaxation, with EC 50 values Ϸ1 mol/L for all 4 regioisomers, whereas Campbell et al 5 and Weintraub et al 18 showed similar results using bovine and porcine conduit coronary arteries. In contrast, we found that in canine coronary arterioles, the EC 50 values for the 4 EET regioisomers ranged between 1 and 100 pmol/L (Table 1) , Ϸ1000-to 10 000-fold lower than the values reported for conduit coronary arteries. We investigated whether the markedly-enhanced EET potency observed in the present study could have resulted from an indirect effect of EETs to stimulate the production of EDRF, as was suggested by Graier et al. 29 However, we found that 14,15-EET produced equipotent vasodilation of endothelium-denuded arterioles, suggesting that the compound acted directly on the vascular smooth muscle cells, an observation that is consistent with reports in canine, bovine, and porcine conduit coronary arteries. 3, 5, 18 It was possible that the markedly enhanced EET potency could have been due to a nonspecific augmentation in the vasodilatory capacity of coronary arterioles as compared with conduit coronary artery responses. Such augmented vasodilatory capacity could be an inherent attribute of the arterioles, or it could stem from differences in the methodology used to examine responses in microvessels as compared with conduit arterial rings. In the present experiments, the coronary microvessels were pressurized, and vascular reactivity was assessed by measuring changes in vessel diameter; in the studies by Rosolowsky et al, 3 Campbell et al, 5 and Weintraub et al 18 arterial rings were studied under conditions of isometric tension. However, we found that responses to SNP did not differ in coronary microvessels as compared with conduit coronary arteries, suggesting that the markedly enhanced EET and DHET potency in arterioles is not due to nonspecific enhancement in smooth muscle sensitivity or differences in experimental methodology.
Selective differences in agonist-induced vasodilation between conduit coronary arteries and coronary arterioles may be present. Interestingly, AA, Ach, and A23187 have been demonstrated to mediate endothelium-dependent coronary vasorelaxation independently of nitric oxide production and/or through the production of EDHF. 30 -37 Moreover, previous studies suggest that endothelium-dependent, nitric oxide-independent vasorelaxation responses that are attributed to EDHF are more prominent in smaller blood vessels in rabbit and rat. 21,22,38 -40 Recently, Nagao et al 21 reported that smaller blood vessels exhibited enhanced potency to aprikalim, an agonist that produces vasorelaxation through activation of ATP-sensitive K ϩ channels, suggesting that small arteries are more sensitive to the actions of hyperpolarizing vasodilators than are large arteries. Therefore, a plausible explanation for the moderately enhanced potencies of AA, Ach, and A23187 in coronary arterioles is that these agonists stimulate the formation of EDHF, which, in turn, produces more potent dilation of arterioles than conduit arteries.
We also report for the first time that 14,15-DHET, 11,12-DHET, 8,9-DHET, and the ␦-lactone of 5,6-EET are potent dilators of resistance blood vessels. In previous studies, it was reported that DHETs did not produce vasorelaxation of rabbit aorta, rat mesenteric microvessels, or the isolated perfused rat tail artery. 14 -16 Based on these observations, it was proposed that the conversion of EETs to DHETs may serve as a mechanism whereby EETs are rendered inactive within the vasculature.
12,27 However, we recently reported that DHETs are incorporated into vascular endothelial phospholipids, where they may be released by bradykinin and potentate vasodilatory responses. 18, 41 However, 11,12-DHET and 14,15-DHET produced comparable amounts of vasorelaxation as their parent EETs in porcine coronary arteries. 17, 18 In the present study, we found that the DHET regioisomers were as potent as (or, in the case of 11,12-DHET, more potent than) their parent EETs in canine coronary arterioles. We are unaware of any endogenous compound that produces vasodilation as potently as that produced by 11,12-DHET. These results suggest that both EETs and DHETs are capable of regulating coronary arteriolar tone by hyperpolarizing vascular smooth muscle. Furthermore, our results with KCl and charybdotoxin suggest that the dilatory responses to 11,12-EET and 11,12-DHET were mediated by activation of K Ca channels.
Cultured vascular smooth muscle and endothelial cells rapidly convert EETs into DHETs. 12, 13, 17, 18 We recently reported that after a 3-minute incubation of porcine coronary artery smooth muscle cells with 1 mol/L [ 3 H]14,15-EET, 8% of the radioactivity recovered in the medium already had been converted to [ 3 H]14,15-DHET. 42 These findings, together with the current observation that 11,12-DHET is far more potent than its parent compound, 11,12-EET, in coronary microvessels, raised the possibility that the 11,12-EETinduced vasodilation might be mediated by its diol metabolite. However, the epoxide hydrolase inhibitor 4-PCO, which effectively blocked DHET formation in canine coronary arteries, did not inhibit vasodilation to 11,12-EET in coronary microvessels. Thus, although conversion of 11,12-EET to 11,12-DHET yields a more potent vasodilator compound in canine coronary microvessels, the mechanism of the 11,12-EET-induced vasodilation is not dependent on the formation of 11,12-DHET.
In summary, the 4 EET regioisomers, and their diol metabolites, produced extremely potent vasodilation of canine coronary arterioles. The vasodilation, which was Ϸ10 000-fold more potent than has been reported in conduit coronary arteries, was mediated by activation of vascular smooth muscle K Ca channels. The preferential ability of these compounds to dilate resistance arterioles suggests that they may contribute to the physiological and/or pathophysiologic regulation of coronary microcirculation.
